


Observed mutations in tumors

Plot


Table



Cancer Distribution

Open in [Advanced Search](#)

761 DONORS AFFECTED BY **1,200** MUTATIONS ACROSS **61** PROJECTS



Showing **1 - 10** of **61** projects



| Project | Site | Tumour Type | Tumour Subtype | # Donors affected ▼ | # Mutations |
|---------|--------------|----------------------|---|---------------------|-------------|
| MELA-AU | Skin | Skin cancer | Melanoma | 112 / 183 (61.20%) | 452 |
| LMS-FR | Mesenchymal | Soft Tissue cancer | Leiomyosarcoma | 29 / 67 (43.28%) | 35 |
| SKCA-BR | Skin | Melanoma | | 41 / 100 (41.00%) | 157 |
| UTCA-FR | Uterus | Uterine cancer | Carcinosarcoma | 4 / 20 (20.00%) | 4 |
| BTCA-SG | Gall Bladder | Biliary Tract cancer | Gall bladder cancer / Cholangiocarcinoma | 12 / 71 (16.90%) | 8 |
| OV-AU | Ovary | Ovarian cancer | Serous cystadenocarcinoma | 14 / 93 (15.05%) | 14 |
| LUSC-KR | Lung | Lung cancer | Adenocarcinoma, Squamous cell carcinoma | 20 / 170 (11.76%) | 20 |
| LIRI-JP | Liver | Liver cancer | Hepatocellular carcinoma (Virus associated) | 30 / 258 (11.63%) | 38 |
| ESAD-UK | Esophagus | Esophageal cancer | Esophageal adenocarcinoma | 47 / 409 (11.49%) | 62 |
| SKCM-US | Skin | Skin cancer | Cutaneous melanoma | 52 / 466 (11.16%) | 55 |

Showing **11 - 20** of **61** projects

| Project | Site | Tumour Type | Tumour Subtype | # Donors affected ▼ | # Mutations |
|---------|------------|------------------------|---|---------------------|-------------|
| LICA-CN | Liver | Liver cancer | Hepatocellular carcinoma HBV-associated | 42 / 402 (10.45%) | 54 |
| MALY-DE | Blood | Malignant Lymphoma | Germinal center B-cell derived lymphomas | 20 / 241 (8.30%) | 24 |
| COCA-CN | Colorectal | Colorectal cancer | Adenocarcinoma, non-Western | 26 / 321 (8.10%) | 22 |
| UCEC-US | Uterus | Endometrial cancer | Uterine corpus endometrial carcinoma | 39 / 531 (7.34%) | 50 |
| GACA-CN | Stomach | Gastric cancer | Intestinal- and diffuse-type | 8 / 123 (6.50%) | 8 |
| LICA-FR | Liver | Liver cancer | Hepatocellular carcinoma (Secondary to alcohol and adiposity) | 13 / 252 (5.16%) | 14 |
| READ-US | Colorectal | Rectal cancer | Adenocarcinoma | 6 / 143 (4.20%) | 7 |
| BRCA-FR | Breast | Breast cancer | Subtype defined by an amplification of the HER2 gene | 3 / 72 (4.17%) | 5 |
| BRCA-EU | Breast | Breast cancer | ER+ve, HER2-ve | 23 / 569 (4.04%) | 24 |
| PBCA-DE | Brain | Pediatric Brain Tumors | Medulloblastoma & Pediatric Pilocytic Astrocytoma | 20 / 499 (4.01%) | 18 |

Showing 10  rows

<<< < 1 2 3 4 5 > >>>

Showing **21 - 30** of **61** projects Filter table

| Project | Site | Tumour Type | Tumour Subtype | # Donors affected ▼ | # Mutations |
|-------------------------|----------|------------------------|---|---------------------|-------------|
| NKTL-SG | Blood | Blood cancer | T-cell and NK-cell lymphoma | 2 / 50 (4.00%) | 2 |
| LAML-KR | Blood | Blood cancer | Acute myeloid leukaemia | 8 / 205 (3.90%) | 27 |
| PAEN-AU | Pancreas | Pancreatic cancer | Endocrine neoplasms | 2 / 52 (3.85%) | 2 |
| PBCA-US | Brain | Pediatric Brain Tumor | Multiple subtypes | 7 / 186 (3.76%) | 35 |
| GACA-JP | Stomach | Gastric cancer | Multiple histological subtypes (Adenocarcinoma and specific subtypes by WHO classification) | 22 / 585 (3.76%) | 18 |
| PACA-CA | Pancreas | Pancreatic cancer | Ductal adenocarcinoma | 10 / 268 (3.73%) | 11 |
| PRAD-UK | Prostate | Prostate cancer | Adenocarcinoma | 5 / 140 (3.57%) | 5 |
| BRCA-UK | Breast | Breast cancer | Triple Negative/lobular/other | 5 / 141 (3.55%) | 5 |
| LINC-JP | Liver | Liver cancer | Hepatocellular carcinoma (Virus associated) | 12 / 394 (3.05%) | 12 |
| PAEN-IT | Pancreas | Rare Pancreatic Tumors | Enteropancreatic endocrine tumors and rare pancreatic exocrine tumors | 1 / 37 (2.70%) | 1 |

Showing **10** ▼ rows<<< < 1 2 **3** 4 5 > >>>

Showing **31 - 40** of **61** projects

| Project | Site | Tumour Type | Tumour Subtype | # Donors affected ▼ | # Mutations |
|-------------------------|---------------|----------------------|---|---------------------|-------------|
| STAD-US | Stomach | Gastric cancer | Adenocarcinoma | 11 / 439 (2.51%) | 11 |
| LUAD-US | Lung | Lung cancer | Adenocarcinoma | 12 / 516 (2.33%) | 13 |
| PRAD-CA | Prostate | Prostate cancer | Adenocarcinoma | 7 / 306 (2.29%) | 7 |
| ORCA-IN | Head and neck | Oral cancer | Gingivobuccal | 4 / 178 (2.25%) | 4 |
| COAD-US | Colorectal | Colon cancer | Adenocarcinoma | 9 / 402 (2.24%) | 11 |
| BLCA-US | Bladder | Bladder cancer | Invasive Urothelial Bladder cancer | 9 / 411 (2.19%) | 9 |
| RECA-EU | Kidney | Renal cancer | Renal cell carcinoma (Focus on but not limited to clear cell subtype) | 9 / 422 (2.13%) | 11 |
| BTCA-JP | Gall Bladder | Biliary Tract cancer | Multiple histological subtypes | 5 / 239 (2.09%) | 5 |
| GBM-US | Brain | Brain cancer | Glioblastoma multiforme | 8 / 388 (2.06%) | 8 |
| THCA-CN | Head and neck | Thyroid cancer | Papillary carcinoma | 1 / 50 (2.00%) | 1 |

Showing 10  rows

<<< < 2 3 4 5 6 > >>>

Showing 10 rows

Showing **51** - **61** of **61** projects Filter table

| Project | Site | Tumour Type | Tumour Subtype | # Donors affected ▼ | # Mutations |
|-------------------------|---------------|------------------------------|-------------------------------------|---------------------|-------------|
| THCA-US | Head and neck | Head and Neck cancer | Thyroid carcinoma | 3 / 492 (0.61%) | 3 |
| PRAD-US | Prostate | Prostate cancer | Adenocarcinoma | 3 / 497 (0.60%) | 3 |
| LGG-US | Brain | Brain cancer | Lower grade glioma | 3 / 508 (0.59%) | 4 |
| CLLE-ES | Blood | Chronic Lymphocytic Leukemia | CLL with mutated and unmutated IgVH | 3 / 510 (0.59%) | 3 |
| PAAD-US | Pancreas | Pancreatic cancer | Adenocarcinoma | 1 / 177 (0.56%) | 1 |
| OV-US | Ovary | Ovarian cancer | Serous cystadenocarcinoma | 2 / 426 (0.47%) | 2 |
| BRCA-US | Breast | Breast cancer | Ductal & lobular | 4 / 1,020 (0.39%) | 4 |
| KIRP-US | Kidney | Renal cancer | Papillary carcinoma | 1 / 278 (0.36%) | 1 |
| CESC-US | Cervix | Cervical cancer | Cervical squamous cell carcinoma | 1 / 289 (0.35%) | 1 |
| ESCA-CN | Esophagus | Esophageal cancer | Squamous carcinoma | 1 / 332 (0.30%) | 1 |
| KIRC-US | Kidney | Renal cancer | Clear cell carcinoma | 1 / 361 (0.28%) | 1 |

Showing **25** ▼ rows

<<<

<

1

2

3

>

>>>